<DOC>
	<DOCNO>NCT01421667</DOCNO>
	<brief_summary>This open-label , multicenter , phase 2 clinical trial evaluate efficacy safety brentuximab vedotin single agent patient CD30-positive non-Hodgkin lymphoma ( NHL ) ( Part A ) . The study also evaluate safety efficacy brentuximab vedotin combination rituximab patient relapse refractory diffuse large B-cell lymphoma ( DLBCL ) ( Part B ) well evaluate correlation CD30 expression response DLBCL ( Part C ) .</brief_summary>
	<brief_title>A Study Brentuximab Vedotin Relapsed Refractory Non-Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologicallyconfirmed NHL ( DLBCL Parts B C ) Relapsed refractory disease follow least 1 prior systemic therapy Measurable disease least 1.5 cm document CT Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 History another primary invasive malignancy remission least 3 year Current diagnosis systemic cutaneous anaplastic large cell lymphoma mycosis fungoides B cell lymphoma previously treat singleagent rituximab ( patient receive brentuximab vedotin ) corticosteroid monotherapy Known cerebral/meningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Monomethyl auristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Lymphoma , T-Cell</keyword>
</DOC>